Eda is a life sciences specialist lawyer with more than ten years’ experience in the sector.
Eda is an expert with respect to all regulatory issues that may be of interest to pharma, medical device, IVDs and life science businesses, including (early) benefit assessment, market access strategies, prescription of drugs and medical devices and eligibility for reimbursement. Further, she assists in every stage of the product life-cycle and advises pharma businesses, medical device and other life sciences businesses on challenges in terms of reimbursement and social law.
Expertise
Industries
Experience
Pro bono
- Eda is a member of the Pro Bono Steering Committee in Germany
Published Work
- Zhuleku E. (2020) “Covid-19 and the Life Science Sector „Covid-19 and the Life Science Sector”, Practical Law ? London, Thomson Reuters
- Zhuleku E, Professor Ehlers A, (2018) „Neues Bundesdatenschutzgesetz und EU?Datenschutzverordnung Anpassungsbedarf bei den Unternehmen“ in pharmind Nr. 1, 82 , Edition Cantor Verlag
- Zhuleku E, Professor Ehlers A, (2016) „Die FSA?Kodizes und ihre Durchsetzung – wie konsequent ist das“ in: pharmind Nr. 6, 869, Edition Cantor Verlag
- Zhuleku E, (2014) Die ärztliche Aufklärungspflicht nach dem Patientenrechtegesetz“ in: Der Diabetologe, Springer Medizin
Speaking Engagements
- Lecturer, Health Care Management at the European Business School (EBS)
- Lecturer, Drug Regulatory Affairs – Basic Course at the University of Augsburg
Qualifications
Admissions
Certified Lawyer for Life Sciences since 2018
Disclaimer
A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.